Payment overview · 2025
General Payments
$193.50
8 reported records · 6 companies
Healthcare provider profile · identity verified
Mir Abdul Karim Moshref, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WAYNE, IN · NPI 1073610689
Verified facts
What the public records show
CMS Open Payments records show Mir Abdul Karim Moshref, MD received $193.50 in general payments during 2025 across 8 reported records.
Axsome Therapeutics, Inc. accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.04 | 39.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.96 | 13.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.03 | 12.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.85 | 12.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.74 | 12.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.88 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.50 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.04 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.91 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 95 |
| Eliquis | Apixaban | 363 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 76 |
| Gabapentin | Gabapentin | 297 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 17 |
| Omeprazole | Omeprazole | 258 | 73 |
| Lisinopril | Lisinopril | 226 | 62 |
| Furosemide | Furosemide | 209 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 44 |
| Losartan Potassium | Losartan Potassium | 177 | 50 |
| Metformin Hcl | Metformin Hcl | 168 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 35 |
| Donepezil Hcl | Donepezil Hcl | 153 | 35 |
| Famotidine | Famotidine | 134 | 31 |
| Allopurinol | Allopurinol | 129 | 24 |
| Spironolactone | Spironolactone | 128 | 27 |
| Potassium Chloride | Potassium Chloride | 122 | 40 |
| Carvedilol | Carvedilol | 116 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 17 |
| Trazodone Hcl | Trazodone Hcl | 110 | 33 |
| Xarelto | Rivaroxaban | 107 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 34 |
| Levetiracetam | Levetiracetam | 96 | 15 |
| Meloxicam | Meloxicam | 96 | 22 |
| Tramadol Hcl | Tramadol Hcl | 88 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Alendronate Sodium | Alendronate Sodium | 79 | 15 |
| Alprazolam | Alprazolam | 76 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 15 |
| Lovastatin | Lovastatin | 70 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 17 |
| Simvastatin | Simvastatin | 67 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 18 |
| Glimepiride | Glimepiride | 63 | 14 |
| Azithromycin | Azithromycin | 60 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 17 |
| Bumetanide | Bumetanide | 58 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 13 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 20 |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Prednisone | Prednisone | 54 | 17 |
| Gemtesa | Vibegron | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Insulin Lispro | Insulin Lispro | 48 | suppressed |
| Nabumetone | Nabumetone | 48 | 12 |
| Ondansetron Odt | Ondansetron | 46 | 23 |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Baclofen | Baclofen | 43 | 11 |
| Nystatin | Nystatin | 43 | 20 |
| Mirtazapine | Mirtazapine | 41 | 19 |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Cephalexin | Cephalexin | 39 | 27 |
| Clonidine Hcl | Clonidine Hcl | 39 | 15 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Ibuprofen | Ibuprofen | 36 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Finasteride | Finasteride | 35 | 13 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 13 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 17 |
| Midodrine Hcl | Midodrine Hcl | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 15 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 11 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | 11 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Cefdinir | Cefdinir | 15 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acetic Acid | Acetic Acid | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.50 · 8 records | Axsome Therapeutics, Inc. | Auvelity, CREON, LINZESS, REXULTI, VYNDAMAX, ZENPEP | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error